Published in Retrovirology on December 17, 2008
Human cellular restriction factors that target HIV-1 replication. BMC Med (2009) 1.86
Resistance to integrase inhibitors. Viruses (2010) 1.75
Impact of Y143 HIV-1 integrase mutations on resistance to raltegravir in vitro and in vivo. Antimicrob Agents Chemother (2009) 1.50
Novel approaches to inhibiting HIV-1 replication. Antiviral Res (2009) 1.48
Host hindrance to HIV-1 replication in monocytes and macrophages. Retrovirology (2010) 1.33
Non-catalytic site HIV-1 integrase inhibitors disrupt core maturation and induce a reverse transcription block in target cells. PLoS One (2013) 1.29
Raltegravir, elvitegravir, and metoogravir: the birth of "me-too" HIV-1 integrase inhibitors. Retrovirology (2009) 1.29
Intrinsic sequence specificity of the Cas1 integrase directs new spacer acquisition. Elife (2015) 1.12
Retroviral integration site selection. Viruses (2010) 1.10
Cross-resistance profile determination of two second-generation HIV-1 integrase inhibitors using a panel of recombinant viruses derived from raltegravir-treated clinical isolates. Antimicrob Agents Chemother (2010) 1.08
Comparative biochemical analysis of HIV-1 subtype B and C integrase enzymes. Retrovirology (2009) 1.05
Quantitative analysis of the time-course of viral DNA forms during the HIV-1 life cycle. Retrovirology (2013) 1.05
Current perspectives on HIV-1 antiretroviral drug resistance. Viruses (2014) 1.04
Properties and functions of the nucleocapsid protein in virus assembly. RNA Biol (2010) 1.02
Biochemical and virological analysis of the 18-residue C-terminal tail of HIV-1 integrase. Retrovirology (2009) 0.99
Sequential deletion of the integrase (Gag-Pol) carboxyl terminus reveals distinct phenotypic classes of defective HIV-1. J Virol (2011) 0.97
Integrase inhibitors effective against human T-cell leukemia virus type 1. Antimicrob Agents Chemother (2011) 0.97
Inhibiting the HIV integration process: past, present, and the future. J Med Chem (2013) 0.93
DNA double strand break repair enzymes function at multiple steps in retroviral infection. Retrovirology (2009) 0.89
Early reverse transcription is essential for productive foamy virus infection. PLoS One (2010) 0.87
Allosteric modulation of protein oligomerization: an emerging approach to drug design. Front Chem (2014) 0.84
HIV-1 Integrase-DNA Recognition Mechanisms. Viruses (2009) 0.84
Integrase Strand Transfer Inhibitors in HIV Therapy. Infect Dis Ther (2013) 0.83
Implications of the nucleocapsid and the microenvironment in retroviral reverse transcription. Viruses (2010) 0.83
A protein ballet around the viral genome orchestrated by HIV-1 reverse transcriptase leads to an architectural switch: from nucleocapsid-condensed RNA to Vpr-bridged DNA. Virus Res (2012) 0.83
A cooperative and specific DNA-binding mode of HIV-1 integrase depends on the nature of the metallic cofactor and involves the zinc-containing N-terminal domain. Nucleic Acids Res (2010) 0.83
Treatment with suboptimal doses of raltegravir leads to aberrant HIV-1 integrations. Proc Natl Acad Sci U S A (2013) 0.82
Cellular cofactors of lentiviral integrase: from target validation to drug discovery. Mol Biol Int (2012) 0.81
Changes in the accessibility of the HIV-1 Integrase C-terminus in the presence of cellular proteins. Retrovirology (2010) 0.81
Consensus HIV-1 FSU-A integrase gene variants electroporated into mice induce polyfunctional antigen-specific CD4+ and CD8+ T cells. PLoS One (2013) 0.80
Short regions of sequence identity between the genomes of bacteria and human. Curr Microbiol (2010) 0.79
Prospective strategies for targeting HIV-1 integrase function. Future Med Chem (2010) 0.78
Retroviral vectors and transposons for stable gene therapy: advances, current challenges and perspectives. J Transl Med (2016) 0.78
Crystal structures of catalytic core domain of BIV integrase: implications for the interaction between integrase and target DNA. Protein Cell (2010) 0.78
Clinical Use of Inhibitors of HIV-1 Integration: Problems and Prospects. Acta Naturae (2011) 0.78
Different Pathways Leading to Integrase Inhibitors Resistance. Front Microbiol (2017) 0.77
HIV-1 integrase modulates the interaction of the HIV-1 cellular cofactor LEDGF/p75 with chromatin. Retrovirology (2011) 0.77
Dynamic Oligomerization of Integrase Orchestrates HIV Nuclear Entry. Sci Rep (2016) 0.76
The Need for Development of New HIV-1 Reverse Transcriptase and Integrase Inhibitors in the Aftermath of Antiviral Drug Resistance. Scientifica (Cairo) (2012) 0.76
Metals in proteins: cluster analysis studies. J Mol Model (2010) 0.76
Yeast and the AIDS virus: the odd couple. J Biomed Biotechnol (2012) 0.76
The dynamics of interconverting D- and E-forms of the HIV-1 integrase N-terminal domain. Eur Biophys J (2014) 0.76
HIV Genome-Wide Protein Associations: a Review of 30 Years of Research. Microbiol Mol Biol Rev (2016) 0.75
Raltegravir in combination with other antiretroviral agents for the treatment of HIV infection. Infect Drug Resist (2010) 0.75
Development and Identification of a Novel Anti-HIV-1 Peptide Derived by Modification of the N-Terminal Domain of HIV-1 Integrase. Front Microbiol (2016) 0.75
Combination dolutegravir-abacavir-lamivudine in the management of HIV/AIDS: clinical utility and patient considerations. Patient Prefer Adherence (2015) 0.75
Mechanisms of LTR-Retroelement Transposition: Lessons from Drosophila melanogaster. Viruses (2017) 0.75
In-silico Comparative Study and Quantitative Structure-activity Relationship Analysis of Some Structural and Physiochemical Descriptors of Elvitegravir Analogs. J Young Pharm (2011) 0.75
Toward Personalized Gene Therapy: Characterizing the Host Genetic Control of Lentiviral-Vector-Mediated Hepatic Gene Delivery. Mol Ther Methods Clin Dev (2017) 0.75
Characterization of the Drug Resistance Profiles of Integrase Strand Transfer Inhibitors in Simian Immunodeficiency Virus SIVmac239. J Virol (2015) 0.75
HIV-1 resistance to dolutegravir is affected by cellular histone acetyltransferase activity. J Virol (2017) 0.75
Structural dynamics of native and V260E mutant C-terminal domain of HIV-1 integrase. J Comput Aided Mol Des (2015) 0.75
Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature (1997) 15.49
Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science (2000) 7.01
HIV-1 DNA integration: mechanism of viral DNA cleavage and DNA strand transfer. Cell (1991) 6.54
Association of integrase, matrix, and reverse transcriptase antigens of human immunodeficiency virus type 1 with viral nucleic acids following acute infection. Proc Natl Acad Sci U S A (1993) 6.44
Human immunodeficiency virus type 1 preintegration complexes: studies of organization and composition. J Virol (1997) 5.73
Binding and stimulation of HIV-1 integrase by a human homolog of yeast transcription factor SNF5. Science (1994) 5.47
Reversal of integration and DNA splicing mediated by integrase of human immunodeficiency virus. Science (1992) 4.97
HIV-1 integrase forms stable tetramers and associates with LEDGF/p75 protein in human cells. J Biol Chem (2002) 4.91
Identification of discrete functional domains of HIV-1 integrase and their organization within an active multimeric complex. EMBO J (1993) 4.39
Retroviral integrase domains: DNA binding and the recognition of LTR sequences. Nucleic Acids Res (1991) 4.39
HIV nuclear import is governed by the phosphotyrosine-mediated binding of matrix to the core domain of integrase. Cell (1995) 4.25
An essential role for LEDGF/p75 in HIV integration. Science (2006) 4.18
LEDGF/p75 functions downstream from preintegration complex formation to effect gene-specific HIV-1 integration. Genes Dev (2007) 3.96
Human immunodeficiency virus integrase protein requires a subterminal position of its viral DNA recognition sequence for efficient cleavage. J Virol (1991) 3.89
Retroviral DNA integration: reaction pathway and critical intermediates. EMBO J (2006) 3.68
Diketo acid inhibitor mechanism and HIV-1 integrase: implications for metal binding in the active site of phosphotransferase enzymes. Proc Natl Acad Sci U S A (2002) 3.40
Complementation between HIV integrase proteins mutated in different domains. EMBO J (1993) 3.32
Crystal structure of the HIV-1 integrase catalytic core and C-terminal domains: a model for viral DNA binding. Proc Natl Acad Sci U S A (2000) 3.26
Quantitative four-dimensional tracking of cytoplasmic and nuclear HIV-1 complexes. Nat Methods (2006) 3.24
Structure of a two-domain fragment of HIV-1 integrase: implications for domain organization in the intact protein. EMBO J (2001) 3.23
Structural basis for the recognition between HIV-1 integrase and transcriptional coactivator p75. Proc Natl Acad Sci U S A (2005) 3.18
A previously unidentified host protein protects retroviral DNA from autointegration. Proc Natl Acad Sci U S A (1998) 3.10
Human immunodeficiency virus integrase directs integration to sites of severe DNA distortion within the nucleosome core. Proc Natl Acad Sci U S A (1994) 3.04
HIV-1 integrase inhibitors that compete with the target DNA substrate define a unique strand transfer conformation for integrase. Proc Natl Acad Sci U S A (2000) 3.00
Three new structures of the core domain of HIV-1 integrase: an active site that binds magnesium. Proc Natl Acad Sci U S A (1998) 2.98
Sequence specificity of viral end DNA binding by HIV-1 integrase reveals critical regions for protein-DNA interaction. EMBO J (1998) 2.84
Human immunodeficiency virus type 1 integrase mutants retain in vitro integrase activity yet fail to integrate viral DNA efficiently during infection. J Virol (1996) 2.82
Solution structure of the N-terminal zinc binding domain of HIV-1 integrase. Nat Struct Biol (1997) 2.81
Solution structure of the DNA binding domain of HIV-1 integrase. Biochemistry (1995) 2.69
Symmetrical base preferences surrounding HIV-1, avian sarcoma/leukosis virus, and murine leukemia virus integration sites. Proc Natl Acad Sci U S A (2005) 2.64
Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro. Antimicrob Agents Chemother (2008) 2.61
A naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV-1 integrase. Proc Natl Acad Sci U S A (2004) 2.55
Crystal structures of the catalytic domain of HIV-1 integrase free and complexed with its metal cofactor: high level of similarity of the active site with other viral integrases. J Mol Biol (1998) 2.49
Role of PSIP1/LEDGF/p75 in lentiviral infectivity and integration targeting. PLoS One (2007) 2.48
Zinc folds the N-terminal domain of HIV-1 integrase, promotes multimerization, and enhances catalytic activity. Proc Natl Acad Sci U S A (1996) 2.46
Integrase mutants defective for interaction with LEDGF/p75 are impaired in chromosome tethering and HIV-1 replication. J Biol Chem (2005) 2.44
Critical contacts between HIV-1 integrase and viral DNA identified by structure-based analysis and photo-crosslinking. EMBO J (1997) 2.42
A stable RAG1-RAG2-DNA complex that is active in V(D)J cleavage. Cell (1997) 2.37
Transportin-SR2 imports HIV into the nucleus. Curr Biol (2008) 2.35
Weak palindromic consensus sequences are a common feature found at the integration target sites of many retroviruses. J Virol (2005) 2.29
The interaction of LEDGF/p75 with integrase is lentivirus-specific and promotes DNA binding. J Biol Chem (2005) 2.28
HIV-1 infection requires a functional integrase NLS. Mol Cell (2001) 2.26
LEDGF/p75 interacts with divergent lentiviral integrases and modulates their enzymatic activity in vitro. Nucleic Acids Res (2006) 2.22
The barrier-to-autointegration protein is a host factor for HIV type 1 integration. Proc Natl Acad Sci U S A (1998) 2.21
Human immunodeficiency virus type 1 integrase protein promotes reverse transcription through specific interactions with the nucleoprotein reverse transcription complex. J Virol (1999) 2.16
Coupled integration of human immunodeficiency virus type 1 cDNA ends by purified integrase in vitro: stimulation by the viral nucleocapsid protein. J Virol (1999) 2.13
Integrase inhibitors and cellular immunity suppress retroviral replication in rhesus macaques. Science (2004) 2.12
Barrier-to-autointegration factor (BAF) bridges DNA in a discrete, higher-order nucleoprotein complex. Proc Natl Acad Sci U S A (2000) 2.12
The influence of DNA and nucleosome structure on integration events directed by HIV integrase. J Biol Chem (1994) 2.03
The inner-nuclear-envelope protein emerin regulates HIV-1 infectivity. Nature (2006) 2.02
HIV-1 integrase crosslinked oligomers are active in vitro. Nucleic Acids Res (2005) 1.96
Reassessment of the roles of integrase and the central DNA flap in human immunodeficiency virus type 1 nuclear import. J Virol (2002) 1.91
Processing of viral DNA ends channels the HIV-1 integration reaction to concerted integration. J Biol Chem (2005) 1.84
Determinants of Mg2+-dependent activities of recombinant human immunodeficiency virus type 1 integrase. Biochemistry (2000) 1.78
Human immunodeficiency virus type 1 integrase: arrangement of protein domains in active cDNA complexes. EMBO J (2001) 1.77
The barrier-to-autointegration factor is a component of functional human immunodeficiency virus type 1 preintegration complexes. J Virol (2003) 1.76
HMG protein family members stimulate human immunodeficiency virus type 1 and avian sarcoma virus concerted DNA integration in vitro. J Virol (1999) 1.71
Zn2+ promotes the self-association of human immunodeficiency virus type-1 integrase in vitro. Biochemistry (1997) 1.69
Mapping features of HIV-1 integrase near selected sites on viral and target DNA molecules in an active enzyme-DNA complex by photo-cross-linking. Biochemistry (1997) 1.68
Retroviral DNA integration--mechanism and consequences. Adv Genet (2005) 1.66
Relationship between the oligomeric status of HIV-1 integrase on DNA and enzymatic activity. J Biol Chem (2006) 1.65
Dynamic modulation of HIV-1 integrase structure and function by cellular lens epithelium-derived growth factor (LEDGF) protein. J Biol Chem (2008) 1.61
Oligomeric states of the HIV-1 integrase as measured by time-resolved fluorescence anisotropy. Biochemistry (2000) 1.57
Efficient concerted integration by recombinant human immunodeficiency virus type 1 integrase without cellular or viral cofactors. J Virol (2002) 1.56
Development of resistance against diketo derivatives of human immunodeficiency virus type 1 by progressive accumulation of integrase mutations. J Virol (2003) 1.54
Complementation of integrase function in HIV-1 virions. EMBO J (1997) 1.46
Inhibition of HIV-1 integrase by flavones, caffeic acid phenethyl ester (CAPE) and related compounds. Biochem Pharmacol (1994) 1.46
Virus evolution reveals an exclusive role for LEDGF/p75 in chromosomal tethering of HIV. PLoS Pathog (2007) 1.41
Interaction of human immunodeficiency virus type 1 integrase with cellular nuclear import receptor importin 7 and its impact on viral replication. J Biol Chem (2007) 1.40
Acetylation of HIV-1 integrase by p300 regulates viral integration. EMBO J (2005) 1.39
Integration requires a specific interaction of the donor DNA terminal 5'-cytosine with glutamine 148 of the HIV-1 integrase flexible loop. J Biol Chem (2005) 1.38
Efficient magnesium-dependent human immunodeficiency virus type 1 integrase activity. J Virol (1995) 1.38
DNA binding induces dissociation of the multimeric form of HIV-1 integrase: a time-resolved fluorescence anisotropy study. Proc Natl Acad Sci U S A (2001) 1.31
Integrase-specific enhancement and suppression of retroviral DNA integration by compacted chromatin structure in vitro. J Virol (2004) 1.31
Foamy viruses--a world apart. Curr Opin Microbiol (2004) 1.31
Structural analyses of purified human immunodeficiency virus type 1 intracellular reverse transcription complexes. J Virol (2003) 1.27
Both the structure and DNA binding function of the barrier-to-autointegration factor contribute to reconstitution of HIV type 1 integration in vitro. J Biol Chem (2000) 1.22
Transcriptional coactivator LEDGF/p75 modulates human immunodeficiency virus type 1 integrase-mediated concerted integration. J Virol (2007) 1.21
Characterization of the nuclear import pathway for HIV-1 integrase. J Biol Chem (2001) 1.20
Host proteins interacting with the Moloney murine leukemia virus integrase: multiple transcriptional regulators and chromatin binding factors. Retrovirology (2008) 1.20
Modeling the late steps in HIV-1 retroviral integrase-catalyzed DNA integration. J Biol Chem (2000) 1.19
Retroviral cDNA integration: stimulation by HMG I family proteins. J Virol (2000) 1.19
Kinetic study of the HIV-1 DNA 3'-end processing. FEBS J (2006) 1.18
Factors responsible for target site selection in Tn10 transposition: a role for the DDE motif in target DNA capture. EMBO J (1997) 1.16
Inhibition of early steps of HIV-1 replication by SNF5/Ini1. J Biol Chem (2006) 1.16
Specificity of interaction of INI1/hSNF5 with retroviral integrases and its functional significance. J Virol (2004) 1.14
Modeling HIV-1 integrase complexes based on their hydrodynamic properties. Biopolymers (2003) 1.14
The metal ion-induced cooperative binding of HIV-1 integrase to DNA exhibits a marked preference for Mn(II) rather than Mg(II). J Biol Chem (1996) 1.14
Inhibition of the human immunodeficiency virus type 1 integrase by guanosine quartet structures. Biochemistry (1996) 1.13
Structure-activity relationships and binding mode of styrylquinolines as potent inhibitors of HIV-1 integrase and replication of HIV-1 in cell culture. J Med Chem (2000) 1.12
Insight into the integrase-DNA recognition mechanism. A specific DNA-binding mode revealed by an enzymatically labeled integrase. J Biol Chem (2008) 1.12
The integrase interactor 1 (INI1) proteins facilitate Tat-mediated human immunodeficiency virus type 1 transcription. Retrovirology (2006) 1.09
HIV-1 integrase inhibitors: update and perspectives. Adv Pharmacol (2008) 1.08
A cellular microRNA mediates antiviral defense in human cells. Science (2005) 8.48
TRIM family proteins: retroviral restriction and antiviral defence. Nat Rev Microbiol (2005) 4.89
Characterization of reemerging chikungunya virus. PLoS Pathog (2007) 3.22
Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro. Antimicrob Agents Chemother (2008) 2.61
The G140S mutation in HIV integrases from raltegravir-resistant patients rescues catalytic defect due to the resistance Q148H mutation. Nucleic Acids Res (2009) 2.00
Early steps of retrovirus replicative cycle. Retrovirology (2004) 1.94
Relationship between the oligomeric status of HIV-1 integrase on DNA and enzymatic activity. J Biol Chem (2006) 1.65
Exosomes as new vesicular lipid transporters involved in cell-cell communication and various pathophysiologies. Biochim Biophys Acta (2013) 1.62
Quasispecies variant dynamics during emergence of resistance to raltegravir in HIV-1-infected patients. J Antimicrob Chemother (2009) 1.59
Restriction of foamy viruses by APOBEC cytidine deaminases. J Virol (2006) 1.52
Impact of Y143 HIV-1 integrase mutations on resistance to raltegravir in vitro and in vivo. Antimicrob Agents Chemother (2009) 1.50
Synthesis and biological activities of a series of 4,5-diaryl-3-hydroxy-2(5H)-furanones. Eur J Med Chem (2007) 1.33
Structural basis for HIV-1 DNA integration in the human genome, role of the LEDGF/P75 cofactor. EMBO J (2009) 1.32
The Escherichia coli RecQ helicase functions as a monomer. J Biol Chem (2003) 1.31
Foamy viruses--a world apart. Curr Opin Microbiol (2004) 1.31
Synthesis and biological evaluation of substituted quinolines: potential treatment of protozoal and retroviral co-infections. Bioorg Med Chem (2003) 1.31
Effect of Ku80 depletion on the preintegrative steps of HIV-1 replication in human cells. Virology (2002) 1.29
Chromatin tethering of incoming foamy virus by the structural Gag protein. Traffic (2008) 1.24
Extracellular ATP acts on P2Y2 purinergic receptors to facilitate HIV-1 infection. J Exp Med (2011) 1.22
Kinetic study of the HIV-1 DNA 3'-end processing. FEBS J (2006) 1.18
Inhibition of human immunodeficiency virus type 1 reverse transcriptase, RNase H, and integrase activities by hydroxytropolones. Antimicrob Agents Chemother (2005) 1.16
Inhibition of early steps of HIV-1 replication by SNF5/Ini1. J Biol Chem (2006) 1.16
Insight into the integrase-DNA recognition mechanism. A specific DNA-binding mode revealed by an enzymatically labeled integrase. J Biol Chem (2008) 1.12
Uncoupling of the base excision and nucleotide incision repair pathways reveals their respective biological roles. Proc Natl Acad Sci U S A (2006) 1.10
Biphasic DNA synthesis in spumaviruses. J Virol (2003) 1.08
Quantitative analysis of the time-course of viral DNA forms during the HIV-1 life cycle. Retrovirology (2013) 1.05
The human polycomb group EED protein interacts with the integrase of human immunodeficiency virus type 1. J Virol (2003) 1.04
Dual inhibition of HIV-1 replication by integrase-LEDGF allosteric inhibitors is predominant at the post-integration stage. Retrovirology (2013) 1.04
Mechanism of HIV-1 integrase inhibition by styrylquinoline derivatives in vitro. Mol Pharmacol (2004) 1.03
G140S/Q148R and N155H mutations render HIV-2 Integrase resistant to raltegravir whereas Y143C does not. Retrovirology (2011) 1.03
Styrylquinolines, integrase inhibitors acting prior to integration: a new mechanism of action for anti-integrase agents. J Virol (2004) 1.02
Centrosomal latency of incoming foamy viruses in resting cells. PLoS Pathog (2007) 1.02
Tax ubiquitylation and SUMOylation control the dynamic shuttling of Tax and NEMO between Ubc9 nuclear bodies and the centrosome. Blood (2010) 1.01
The engagement of activating FcgammaRs inhibits primate lentivirus replication in human macrophages. J Immunol (2006) 1.00
Protease-dependent uncoating of a complex retrovirus. J Virol (2005) 1.00
Natural simian foamy virus infection in wild-caught gorillas, mandrills and drills from Cameroon and Gabon. J Gen Virol (2004) 1.00
Nuclear import of HIV-1 integrase is inhibited in vitro by styrylquinoline derivatives. Mol Pharmacol (2004) 0.99
Cross-species transmission of simian foamy virus to humans in rural Gabon, Central Africa. J Virol (2011) 0.98
Centrosomal pre-integration latency of HIV-1 in quiescent cells. Retrovirology (2007) 0.97
Probing of HIV-1 integrase/DNA interactions using novel analogs of viral DNA. J Biol Chem (2006) 0.97
Target recognition by catechols and beta-ketoenols: potential contribution of hydrogen bonding and Mn/Mg chelation to HIV-1 integrase inhibition. J Med Chem (2007) 0.96
Impairment of human immunodeficiency virus type-1 integrase SUMOylation correlates with an early replication defect. J Biol Chem (2011) 0.95
Disulfide-linked integrase oligomers involving C280 residues are formed in vitro and in vivo but are not essential for human immunodeficiency virus replication. J Virol (2003) 0.95
Efficient and specific internal cleavage of a retroviral palindromic DNA sequence by tetrameric HIV-1 integrase. PLoS One (2007) 0.94
Ku represses the HIV-1 transcription: identification of a putative Ku binding site homologous to the mouse mammary tumor virus NRE1 sequence in the HIV-1 long terminal repeat. J Biol Chem (2001) 0.94
Multiple Escherichia coli RecQ helicase monomers cooperate to unwind long DNA substrates: a fluorescence cross-correlation spectroscopy study. J Biol Chem (2010) 0.93
Intra- and intercellular trafficking of the foamy virus auxiliary bet protein. J Virol (2002) 0.93
Synthesis and HIV-1 integrase inhibitory activities of caffeic acid dimers derived from Salvia officinalis. Bioorg Med Chem Lett (2005) 0.92
A novel function for spumaretrovirus integrase: an early requirement for integrase-mediated cleavage of 2 LTR circles. Retrovirology (2005) 0.92
Integrase inhibitor reversal dynamics indicate unintegrated HIV-1 dna initiate de novo integration. Retrovirology (2015) 0.91
Genetic barriers for integrase inhibitor drug resistance in HIV type-1 B and CRF02_AG subtypes. Antivir Ther (2009) 0.91
New HIV-1 replication inhibitors of the styryquinoline class bearing aroyl/acyl groups at the C-7 position: synthesis and biological activity. Bioorg Med Chem Lett (2005) 0.91
Centrosome and retroviruses: the dangerous liaisons. Retrovirology (2007) 0.90
Hot spots of integrase genotypic changes leading to HIV-2 resistance to raltegravir. Antimicrob Agents Chemother (2010) 0.89
Structural effects of amino acid variations between B and CRF02-AG HIV-1 integrases. J Med Virol (2008) 0.89
Early stages of HIV replication: how to hijack cellular functions for a successful infection. AIDS Rev (2005) 0.88
The (52-96) C-terminal domain of Vpr stimulates HIV-1 IN-mediated homologous strand transfer of mini-viral DNA. Nucleic Acids Res (2003) 0.87
Further characterization of equine foamy virus reveals unusual features among the foamy viruses. J Virol (2002) 0.87
Early reverse transcription is essential for productive foamy virus infection. PLoS One (2010) 0.87
A nuclear export signal within the structural Gag protein is required for prototype foamy virus replication. Retrovirology (2011) 0.86
Reaction of rosmarinic acid with nitrite ions in acidic conditions: discovery of nitro- and dinitrorosmarinic acids as new anti-HIV-1 agents. J Med Chem (2008) 0.86
Comparative proteomic analysis of HIV-1 particles reveals a role for Ezrin and EHD4 in the Nef-dependent increase of virus infectivity. J Virol (2013) 0.86
Development of a fluorescence-based HIV-1 integrase DNA binding assay for identification of novel HIV-1 integrase inhibitors. Antiviral Res (2013) 0.84
Simple criterion for selection of flavonoid compounds with anti-HIV activity. Bioorg Med Chem Lett (2006) 0.84
A protein ballet around the viral genome orchestrated by HIV-1 reverse transcriptase leads to an architectural switch: from nucleocapsid-condensed RNA to Vpr-bridged DNA. Virus Res (2012) 0.83
Chromosomal tethering and proviral integration. Biochim Biophys Acta (2009) 0.83
A cooperative and specific DNA-binding mode of HIV-1 integrase depends on the nature of the metallic cofactor and involves the zinc-containing N-terminal domain. Nucleic Acids Res (2010) 0.83
Use of the Kohonen neural network for rapid screening of ex vivo anti-HIV activity of styrylquinolines. J Med Chem (2002) 0.82
Disruption of HIV-1 integrase-DNA complexes by short 6-oxocytosine-containing oligonucleotides. Biochemistry (2002) 0.82
HIV-1 integrase complexes with DNA dissociate in the presence of short oligonucleotides conjugated to acridine. Biochemistry (2004) 0.82
Isolation of foamy viruses from peripheral blood lymphocytes. Methods Mol Biol (2005) 0.82
The total synthesis of fukiic acid, an HIV-1 integrase inhibitor. Eur J Med Chem (2007) 0.82
Impact of the Ku complex on HIV-1 expression and latency. PLoS One (2013) 0.81
Rational design of a fluorescent NADPH derivative imaging constitutive nitric-oxide synthases upon two-photon excitation. Proc Natl Acad Sci U S A (2012) 0.81
NO formation by neuronal NO-synthase can be controlled by ultrafast electron injection from a nanotrigger. Chembiochem (2009) 0.81
HIV-1 integrase can process a 3'-end crosslinked substrate. Eur J Biochem (2004) 0.80
Synthesis and antiviral properties of some polyphenols related to Salvia genus. Bioorg Med Chem Lett (2008) 0.80
Synthesis and HIV-1 integrase inhibition of novel bis- or tetra-coumarin analogues. Chem Pharm Bull (Tokyo) (2007) 0.80
Structural and theoretical studies of [6-bromo-1-(4-fluorophenylmethyl)-4(1H)-quinolinon-3-yl)]-4-hydroxy-2-oxo-3-butenoïc acid as HIV-1 integrase inhibitor. Bioorg Med Chem Lett (2009) 0.79
Ku80 participates in the targeting of retroviral transgenes to the chromatin of CHO cells. J Virol (2007) 0.79
3' self-inactivating long terminal repeat inserts for the modulation of transgene expression from lentiviral vectors. Hum Gene Ther Methods (2012) 0.78
Long-lasting persistence of integrase resistance mutations in HIV-2-infected patients after raltegravir withdrawal. Antivir Ther (2011) 0.78
In Silico and In Vitro Comparison of HIV-1 Subtypes B and CRF02_AG Integrases Susceptibility to Integrase Strand Transfer Inhibitors. Adv Virol (2012) 0.77
Comparative study of the fatty acid binding process of a new FABP from Cherax quadricarinatus by fluorescence intensity, lifetime and anisotropy. PLoS One (2012) 0.77